Antibiotics Are Man's Greatest Invention
Jackett, P. S., Aber, V. R. & Lowrie, D. B. Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis. J Gen Microbiol 104, 37–45 (1978).
Vandal, O. H., Nathan, C. F. & Ehrt, S. Acid resistance in Mycobacterium tuberculosis. J Bacteriol 191, 4714–4721 (2009).
Gerston, K. F., Blumberg, L., Tshabalala, V. A. & Murray, J. Viability of mycobacteria in formalin-fixed lungs. Hum Pathol 35, 571–575 (2004).
Brennan, P. J. & Nikaido, H. The envelope of mycobacteria. Annu Rev Biochem 64, 29–63 (1995).
Trias, J., Jarlier, V. & Benz, R. Porins in the cell wall of mycobacteria. Science 258, 1479–1481 (1992).
Schaberg, T. Treatment of tuberculosis. Current standards. Internist (Berl) 56, 1379–1388 (2015).
Mahmoudi, A. & Iseman, M. D. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA 270, 65–68 (1993).
Ventola, C. L. The antibiotic resistance crisis: part 1: causes and threats. P T 40, 277–283 (2015).
Brotz-Oesterhelt, H. & Sass, P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol 5, 1553–1579 (2010).
DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J Health Econ 22, 151–185, https://doi.org/10.1016/S0167-6296(02)00126-1 (2003).
WHO. Global Tuberculosis Report 2017 (2017).
Emmerich, R. & Low, O. Bakteriolytische Enzyme als Ursache der erworbenen Immunität und die Heilung von Infectionskrankheiten durch dieselben. Z Hyg Infektionskr 31, 1–65 (1899).
Sukuru, S. C. et al. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity. J Biomol Screen 14, 690–699 (2009).
Rutledge, P. J. & Challis, G. L. Discovery of microbial natural products by activation of silent biosynthetic gene clusters. Nat Rev Microbiol 13, 509–523 (2015).
Mehbub, M. F., Perkins, M. V., Zhang, W. & Franco, C. M. M. New marine natural products from sponges (Porifera) of the order Dictyoceratida (2001 to 2012); a promising source for drug discovery, exploration and future prospects. Biotechnol Adv 34, 473–491 (2016).
Mora, C., Tittensor, D. P., Adl, S., Simpson, A. G. B. & Worm, B. How Many Species Are There on Earth and in the Ocean? PLOS Biology 9, e1001127 (2011).
Kennedy, J. et al. Marine metagenomics: new tools for the study and exploitation of marine microbial metabolism. Mar Drugs 8, 608–628 (2010).
Subramani, R. & Aalbersberg, W. Marine actinomycetes: an ongoing source of novel bioactive metabolites. Microbiol Res 167, 571–580 (2012).
Le Cesne, A. & Reichardt, P. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice. Future Oncol 11, 3–14 (2015).
Chhikara, B. S. & Parang, K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opin Drug Deliv 7, 1399–1414 (2010).
Garrone, O. et al. Eribulin in advanced breast cancer: safety, efficacy and new perspectives. Future Oncol 13, 2759–2769 (2017).
Whitley, R. et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 324, 444–449 (1991).
Evans-Illidge, E. A. et al. Phylogeny drives large scale patterns in Australian marine bioactivity and provides a new chemical ecology rationale for future biodiscovery. PLoS One 8, e73800 (2013).
Capon, R. J. et al. Extraordinary Levels of Cadmium and Zinc in a Marine Sponge, Tedania-Charcoti Topsent – Inorganic Chemical Defense Agents. Experientia 49, 263–264 (1993).
Quinoa, E., Adamczeski, M., Crews, P. & Bakus, G. J. Bengamides, Heterocyclic Anthelmintics from a Jaspidae Marine Sponge. Journal of Organic Chemistry 51, 4494–4497 (1986).
Hu, X. et al. Regulation of c-Src nonreceptor tyrosine kinase activity by bengamide A through inhibition of methionine aminopeptidases. Chem Biol 14, 764–774 (2007).
Lu, J. P. et al. Inhibition of Mycobacterium tuberculosis methionine aminopeptidases by bengamide derivatives. ChemMedChem 6, 1041–1048 (2011).
Towbin, H. et al. Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors. J Biol Chem 278, 52964–52971 (2003).
Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27–55 (1984).
Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360, 2397–2405 (2009).
Conradie, F. et al. Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. S Afr Med J 104, 164–166 (2014).
Ryan, N. J. & Lo, J. H. Delamanid: first global approval. Drugs 74, 1041–1045 (2014).
Palomino, J. C. & Martin, A. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio. Curr Med Chem 20, 3785–3796 (2013).
Thakur, A. N. et al. Antiangiogenic, antimicrobial, and cytotoxic potential of sponge-associated bacteria. Mar Biotechnol (NY) 7, 245–252 (2005).
Wilson, D. M., Puyana, M., Fenical, W. & Pawlik, J. R. Chemical defense of the Caribbean reef sponge Axinella corrugata against predatory fishes. J Chem Ecol 25, 2811–2823 (1999).
Wu, Z. Y., Li, Y. T. & Xu, D. J. Diaqua(2,2′-diamino-4,4′-bi-1,3-thiazole)oxosulfatovanadium(IV) tetrahydrate. Acta Crystallogr C 61, m463–465 (2005).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3, 711–715 (2004).
Isbister, G. K. & Hooper, J. N. Clinical effects of stings by sponges of the genus Tedania and a review of sponge stings worldwide. Toxicon 46, 782–785 (2005).
Dillman, R. L. & Cardellina, J. H. Aromatic Secondary Metabolites from the Sponge Tedania-Ignis. Journal of Natural Products 54, 1056–1061 (1991).
Schmitz, F. J. et al. Metabolites from the Marine Sponge Tedania-Ignis – a New Atisanediol and Several Known Diketopiperazines. Journal of Organic Chemistry 48, 3941–3945 (1983).
Cronan, J. M. Jr. & Cardellina, J. H. II A Novel δ-Lactam from the Sponge Tedania ignis. Natural Product Letters 5, 85–88 (1994).
Chevallier, C. et al. Tedanolide C: A potent new 18-membered-ring cytotoxic macrolide isolated from the Papua New Guinea marine sponge Ircinia sp. Journal of Organic Chemistry 71, 2510–2513 (2006).
Costantino, V. et al. Tedanol: A potent anti-inflammatory ent-pimarane diterpene from the Caribbean Sponge Tedania ignis. Bioorgan Med Chem 17, 7542–7547 (2009).
Parameswaran, P. S., Naik, C. G. & Hegde, V. R. Secondary metabolites from the sponge Tedania anhelans: Isolation and characterization of two novel pyrazole acids and other metabolites. Journal of Natural Products 60, 802–803 (1997).
Tanaka, Y. & Katayama, T. Biochemical Studies on the Carotenoids in Porifera: The Structure of Tedaniaxanthin. Nippon Suisan Gakkaishi 45, 633–634 (1979).
Visamsetti, A., Ramachandran, S. S. & Kandasamy, D. Penicillium chrysogenum DSOA associated with marine sponge (Tedania anhelans) exhibit antimycobacterial activity. Microbiol Res 185, 55–60 (2016).
Kinder, F. R. Jr. et al. Total syntheses of bengamides B and E. J Org Chem 66, 2118–2122 (2001).
Phillips, P. E. et al. Bengamide E arrests cells at the G1/S restriction point and within the G2/M phase of the cell cycle. Proc Annu Meet Am Assoc Cancer Res 41, 59 (2000).
Johnson, T. A. et al. Myxobacteria versus sponge-derived alkaloids: the bengamide family identified as potent immune modulating agents by scrutiny of LC-MS/ELSD libraries. Bioorg Med Chem 20, 4348–4355 (2012).
Dumez, H. et al. A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. Anticancer Drugs 18, 219–225 (2007).
Swinney, D. C. & Anthony, J. How were new medicines discovered? Nat Rev Drug Discov 10, 507–519 (2011).
Bradshaw, R. A., Brickey, W. W. & Walker, K. W. N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families. Trends Biochem Sci 23, 263–267 (1998).
Vaughan, M. D., Sampson, P. B. & Honek, J. F. Methionine in and out of proteins: targets for drug design. Curr Med Chem 9, 385–409 (2002).
Olaleye, O. et al. Methionine Aminopeptidases from Mycobacterium tuberculosis as Novel Antimycobacterial Targets. Chemistry & Biology 17, 86–97 (2010).
Griffith, E. C. et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chemistry & Biology 4, 461–471 (1997).
Sin, N. et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. P Natl Acad Sci USA 94, 6099–6103 (1997).
Polena, H. et al. Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination. Sci Rep 6, 33162 (2016).
Yu, M. et al. Nontoxic Metal-Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant Mycobacterium tuberculosis. J Med Chem 59, 5917–5921 (2016).
Zhang, J. H., Chung, T. D. Y. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening 4, 67–73 (1999).
Hu, X. Y., Addlagatta, A., Matthews, B. W. & Liu, J. O. Identification of pyridinylpyrimidines as inhibitors of human methionine aminopeptidases. Angew Chem Int Edit 45, 3772–3775 (2006).
Kishor, C., Gumpena, R., Reddi, R. & Addlagatta, A. Structural studies of Enterococcus faecalis methionine aminopeptidase and design of microbe specific2,2′-bipyridine based inhibitors. Medchemcomm 3, 1406–1412, https://doi.org/10.1039/c2md20096a (2012).
Reddi, R. et al. Selective targeting of the conserved active site cysteine of Mycobacterium tuberculosis methionine aminopeptidase with electrophilic reagents. Febs J 281, 4240–4248 (2014).